Docstoc

L.Serafini_SMEs participation in FP7 Health

Document Sample
L.Serafini_SMEs participation in FP7 Health Powered By Docstoc
					     Seventh Framework Programme
                 Health Theme and
                  SME participation


                          European Commission
                          Research DG – Health
                              Coordination Unit
                             SMEs & Innovation
                              Ludovica Serafini




June 2009
                  Outline of the presentation

     EU support for research & innovation
        Structure and budget
        Orientation tips
     7th Framework Programme (FP7)
        Opportunities for SMEs
        Results to date
        Key factors for success
        Update on strategy x SMEs
       The Health Theme
       The Innovative Medicine Initiative
       Contacts & Information
       SME definition
2
                                                EU support
                              for Research and Innovation*
           complementary programmes,
                                from research to market.
            The €55 billion Seventh Framework Programme supports basic
             and applied pre-competitive research activities, leverages
             money and concentrate resources on strategic research areas, always
             on the basis of technological and scientific excellence.

            The Competitiveness and Innovation Framework Programme
             supports innovation activities, provides better access to finance
             and delivers business support services in the regions (like the Europe
             Enterprise Network).

            Structural funds have just as much funding as FP7, however FP7
               concentrates on excellence for competitiveness, while the Structural
               Funds' main objective is cohesion.
               Programme management is done by Member States and their Regions.

3   *Check at: http://cordis.europa.eu/eu-funding-guide/home_en.html the “Practical guide to EU funding”
                                         EU support
                        for Research and Innovation
       In addition, support to Financial instruments is provided through…

     Risk Sharing Finance Facility (RSFF) is a joint initiative of the EC (DG
      RTD FP7) and the European Investment Bank (EIB). It is a debt-based facility
      (loans) designed to help financing riskier research & innovation projects. It
      targets all size companies. But large-medium size loans are provided directly
      through EIB, smaller loans through Member States Intermediaries.

     The Entrepreneurship and Innovation Programme (EIP) (DG ENTR
      CIP) provides better access to finance in collaboration with the European
      Investment Fund (EIF) for venture capital and guarantee securisation. Check
      the network of Member States Intermediaries.

     The Joint European Resources for Micro to medium Enterprises
       (JEREMIE) is an initiative of the Commission (DG REGIO) together with the
       EIB and the EIF to provide improved access-to-finance and risk-capital for
       micro business and SMEs in the regions of the EU. Check the network of
       Member States Intermediaries.



4
                             FP7 budget (2007-2013):
                                           €55 billion




    = ~6% of public R&D
      investment in Europe
5
                                                         Orientation tips:
                        Where to apply for research funding?
             Identify your need and the appropriate part of the programme
              eg for SMEs:

                   FP7 Health Theme                  Eureka-Eurostar
                   (Cooperation)                     (Capacities)
                   • Preferred target : high-tech,   • R&D performing
                   research-intensive SMEs           enterprises
                   • Published topics (top-down)     (10% full time equivalent or
    R&D capacity




                                                     annual turnover on R&D)
                                                     • Bottom-up



                        Research for the benefit of SMEs
                        (Capacities)
                        • Support SMEs outsourcing research activities
                        • Bottom-up
                      Approaching Time to commercialization

6
                            Orientation tips:
          Seek opportunities in the whole FP7
          for example in People (Mary Curie)…

    …the INDUSTRY–ACADEMIA
    PARTNERSHIPS &PATHWAYS will help you
      to:
     Build capacity (personnel)
     Technology transfer
     Networking


7
                      Collaborative research in FP7:
                        The Cooperation programme

         Thematic Priorities
    1.   Health                                             6.1
    2.   Food, agriculture, fisheries and biotechnology     1.9
    3.   Information and communication technologies         9.1
    4.   Nanosciences, nanotechnologies, materials
         and new production technologies                    3.5
    5.   Energy                                             2.3
    6.   Environment (including climate change)             1.9
    7.   Transport (including aeronautics)                  4.2
    8.   Socio-economic sciences and the humanities         0.6
    9.   Security & 10. Space                               2.8
             Total for collaborative research             €32.4 billion

8
                        Collaborative research
                              for Health in FP7

Budget:
 €6 billion over 7 years (2007-2013)

Activities in 3 main areas
• Biotechnology, generic tools and technologies for
  human health
• Translating research for human health
• Optimising the delivery of healthcare
                                            The health Theme
                                           structure and content

     Pillar 1 :          Pillar 2 :            Pillar 3 :         Pillar 4 :
 Biotechnology,        Translating          Optimising the       Other actions
 generic tools &       research for           delivery of         across the
technologies for      human health          health care for         theme
                                              European
     health
                                               citizens

  Opportunities for all high-tech, research-intensive SMEs :
          in the areas of brain and related diseases,             Opportunities
infectious diseases, cancer, cardiovascular diseases, diabetes     for all SMEs,
     and obesity, rare diseases, other chronic diseases…          namely for all
                                                                      service
                                                                    companies
         In all technological areas related to health:
          biotechnologies, biomedical engineering,
           medical technologies, bioinformatics…
10
                                     Orientation tips

      Use available support, like National Contact
       Points, SME go Health… (for addresses see end of the
       presentation).

      Match your objectives with the Programme
       funding opportunities.
      Have a clear vision of what and where you
       want to get.
      Do it only if it corresponds to your strategic
       goals.
      Be involved in the conception and
       implementation of the project.
11
                                       Orientation tips

     Kill wrong expectations!


      through FP7 Cooperation, industrial applicants should
       not seek support for company funding
      but rather financial support for collaborative research
       projects, aiming at developing medium/long term
       product portfolio within the scope of the published
       topic.




12
                                               Genewave SA
     SME success stories in Health research:
     How to successfully use EU contribution



     • Coordinated FP6 Quantitative analysis of genes in single
       cells (QUAGSIC)  EC contribution: €1.5m over 2 years
        QUAGSIC aimed to develop methods and instruments for
        providing early diagnosis systems  project completed with the
        development of the PortFastFlu prototype.



     • Is now coordinating the FP7 PORTFASTFLU project  EC
       contribution €3.8 million 3 years project
        PORTFASTFLU aims to develop rapid screening system that will
        revolutionize control of influenza epidemics…


13
     SME success stories in Health research
     How to successfully use EU contribution       BioInvent
     The FP6 project ANGIOSTOP aimed to develop a new, safer and
     more effective medicine for the angio-genic treatment of
     Cancer, Artitis and Ocular Neovascolarization based on
     Inibition of Placental Growth Factor.

     The SME BioInvent successfully coordinated the project
     consisting of uniquely qualified academic research groups together
     with SMEs owning intellectual property, essential know-how and with
     clinical trials experts.

     Project just finished, with very promising lead products …




14
                                  Opportunities for SMEs

                            Policy target :
                   15% of the FP7 budget for SMEs
                    for Health  € 900 millions
                                 FP7 strategy:
     Support research intensive SMEs participation in EU funded projects
     Help SMEs to make a success out of EU funded projects participation

               Renewed emphasis and measures for SMEs
                  Participation encouraged in all areas
                  Special topics for SMEs
                  Support actions
                  Favourable conditions…


15
                              Opportunities for SMEs

     Favourable conditions:
      Medium/long term vision: 7-year programme
      Improved conditions in FP7
        Strong support : up to 75% of R&D costs and up to 100%
         management & training
        Better intellectual rights protection: IPR rules adapted to
         SMEs needs
        Administrative simplification:
         reduced need for financial checks and bank guarantees
         thanks to the garantee fund



16
                                 Key factors for success
                                      in applying for FP7 funding
                                             in the Health Theme
     Competition is tough :
                     only the best projects get funded
      the proposal must be in scope with the topics and the
       workprogramme,
      the consortium of partners must be excellent and
       appropriate for the tasks,
      the proposal must address all 3 criteria,
      convince the evaluators (don’t rely on reputation),
      and, of course, respect the basic rules.
       (deadlines, N° of participants, ceilings, length, ethics…)

17
                                     Key factors for success
                                          in applying for FP7 funding
                                                 in the Health Theme
     Support structures exist :
                           use them!!!
      National Contact Points in the Member States and Associated States,
       provides guidance, practical information and assistance on all aspects of
       participation in the Framework Programmes:
       http://cordis.europa.eu/fp7/ncp_en.html

      SME-go-Health, FP6 EU-funded project, specifically supporting
       participation of SMEs in Health Theme, including IMI. It provides several
       services, including a matchmaking database for proposals preparation.
       Contact them at: http://www.smesgohealth.org/

      SM-BIO-POWER focusses in supporting SMEs in biomedical engineering
       and medical technologies to participate in EU research:
       http://www.smbiopower.com/

18
     FP7 Health Theme:
      Results to date




19
                       Outcome of first 3 years of FP7
                                               Health
       Call            Budget          Proposals          Projects   Success
                                       evaluated          funded     rate*
     1st (2007)       € 641m             893                153      17%
     2nd (2008)       € 577m             865                172      20%
     3rd (2009) 1S    € 493m             513                 95      18.5%
              (2S ~€ 115m**               26 (145)        10-11      ~40%)
     TOTAL:          € 1,711m          2,271                420      18.5%
       * success rate: funded/eligible proposals
       ** two-stage call, 2nd stage evaluation results pending


20
                                  First two FP7 calls
                                     funded projects
             for the Health Theme SME participation:

     FP7 policy driven objective 15% contribution to SMEs
       1st + 2nd calls  325 projects have been funded
            ~ 11% of contribution will go to SMEs
     62% of the projects have at least one SME (202/325)
          13% of participants are SMEs (417/2873)
          About 85% of SMEs are research intensive



21
                                      SME Participation
                             in the 95 short-listed proposals
                                    of 3rd call single-stage *
                              based on proposal information
        15% of participants
        14% of budget requested
        79% of 95 proposals have at least 1 SME
         participant
        7 out of 95 Co-ordinators of proposals are
         SMEs


     * FP7-HEALTH-2009-two-stage evaluations/procedures ongoing
      SME participation not yet available

22
                                                     Update on
                                   FP7 Health strategy for SMEs
                 Enhance SMEs participation:
      Support structures (NCP, SME-go-Health, SM-BIO-Power…)

      Awareness (Bio, EuroBio…)

      Encourage SME participation in all projects

      SME suitable or targeted topics

         Maximise outcomes of EU funded research projects
     • Workshops "SMEs in Health Research”, March 2007, February 2009, Spring
       2011…

     • Educational/Promotional material: Workshop Proceedings, SME call
       catalogue highlighting SME role in projects (model)…

     • Kappa Health (http://www.kappa-health.org/) SA x Assessment and
       Valorisation of Successful SMEs participating into EU-FP Health Projects.


23
     • Support structures (Enterprise Europe Network, SME portal…).
                  Annual calls for proposals
                      in the Health Theme


      1st call (2007 budget): € 641 million
      2nd call (2008 budget): € 577 million
      3rd call (2009 budget): € 610 million


      next call (2010 budget): ~€ 650 million (tbc)
         to be published end-July 2009




24
                               2010 calls for proposals
         FEATURES

      More calls, with different deadlines (!)

      More topics via 2-stage submission/evaluation than 2008
       (€115 => €200m)

      Many topics encourage participation of SMEs (but SME
       participation is welcome in all topics)

      Major effort on structuring cancer research in Europe:
          €100m, including 2 Networks of Excellence

      Coordinated calls: Better Health for Africa & Influenza

      Public-Private Joint Initiatives: COLIPA & IMI
25
                                2010 calls for proposals
                              two main calls:
     FP7-HEALTH-2010-single-stage
         for some areas/topics; expected deadline: 19 Nov. 2009 (tbc)
     FP7-HEALTH-2010-two-stage
         for some areas/topics, deadline for 1st stage: 29 Oct. 2009 (tbc)

                           plus special calls:
     FP7-AFRICA-2010 (coordinated with Food and Environment themes)
         for six topics, expected deadline: 14 Jan. 2010 (tbc)
     FP7-INFLUENZA-2010 (coordinated with Food theme)
         for three topics, expected deadline: 29 Oct. 2009 (tbc)
     FP7-ERANET-2010-RTD (horizontal call)
         for 3 topics, expected deadline: 19 Jan. 2010 (tbc)
     FP7-Health-2010-Joint-Research-Initiative-Commission-
      COLIPA expected deadline: 3 Feb. 2010 (tbc)
     IMI call 2010 dates to be determined…
26
                                                    The Health theme
                                                Structure and content of
                                                 2010 Workprogramme*


            pillar 1:                      pillar 2:         pillar 3:
       Biotechnology,                   Translating         Optimising
        generic tools                   research for       the delivery
       & technologies                  human health       of health care
          for health



      Activity (pillar) 4: Other actions across the theme
      cross-cutting issues: child health, the health of ageing population
                            gender-related health issues

     * Draft info, to check after publication
27
                                   The Health Theme
                      Structure and content of 2010 WP
                                  Pillar 1 :
         1. Biotechnology, generic tools & technologies for health


     1.1 High-Throughput     1.2 Detection diagnosis
     Research                & monitoring               1.3 Suitability, safety,
                                                        efficacy of therapies
     • Human Biobanks (CP)   • Identific. & detection
     • Epidemiology of        of biomarkers             See 4.2 RESPONDING
      multifactorial          (CPs) 2St                 TO EU POLICY NEEDS
      diseases (ERA-NET)     • Biomarkers as            (Pillar 4)
     • Post-translational     candidate for             1.4 INNOVATIVE
      modifications of        clinical                  THERAPEUTIC
      proteins (SICA)         validation (SA)           APPROACHES &
                             • Genetic testing (CA)     INTERVENTIONS
                             • HCV Infections & its     • Cell-based
                              biomarkers (SICA)         immunotherapy (CPs)
28
                                The Health Theme
                   Structure and content of 2010 WP

                           Pillar 2 :
        2. TRANSLATING RESEARCH FOR HUMAN HEALTH 
         2.1 INTEGRATING BIOLOGICAL DATA AND PROCESSES:
          LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY

                          2.1.2 SYSTEMS BIOLOGY
      2.1.1 LARGE-SCALE
      DATA GATHERING
                          • Tackling Human
                            Diseases through
     • Mouse functional
                            SB approaches (CPs) 2St.
      genomics (CP)
                          • Enable SB of complex
     • Standards on
                            biological processes (NoEs) 2 St.
       LSDG (CA).
                          • Mathematical algorishms for SB (SICA).




29
                                    The Health Theme
                       Structure and content of 2010 WP

                                  Pillar 2 :
           2. TRANSLATING RESEARCH FOR HUMAN HEALTH 
            2.2 RESEARCH ON THE BRAIN AND RELATED DISEASES,
                    HUMAN DEVELOPMENT AND AGEING

                          2.2.2 Human development and ageing
     2.2.1 Brain and
      brain-related
                          • Role of early-life developmental processes
        diseases
                           in longevity determination (CP) 2 St.
                          • Homeostasis in human development and
 See 4.2
                           its effects on lifespan (CP) 2 St.
 RESPONDING TO EU
                          • Integrative systems biology and comparative
 POLICY NEEDS
                            genomics for studying HA (CP) 2St.
 (Pillar 4)
                          • Markers of cellular senescence x HA (CP) 2St.
                          • Frailty and its implications in modern
                           society (SA).
30
                                 The Health Theme
                    Structure and content of 2010 WP
                               Pillar 2 :
          2. TRANSLATING RESEARCH FOR HUMAN HEALTH 
         2.3 Translational research in major infectious diseases:
                To confront major threats to public health
                         2.3.2 HIV/AIDS, malaria
 2.3.1 Anti-microbial    and tuberculosis              FP7 coordinated call
   drug resistance                                          for Africa
                         • Target characterisation
       Closed            and hit-to-lead progression
                         in TB Drug Development         • New or Improved
                         (CP)                              Vector Control
                         • Lead optimisation and            Tools (SICA)
                         late preclinical
                         development in TB drugs
                         (CPs)
                         • Cohort studies on
                         HIV/AIDS (NoE)
31
                                 The Health Theme
                    Structure and content of 2010 WP
                                Pillar 2 :
           2. TRANSLATING RESEARCH FOR HUMAN HEALTH 
          2.3 Translational research in major infectious diseases:
                 To confront major threats to public health

     2.3.3 Potentially new and re-        2.3.4 Neglected
     emerging epidemics                   infectious diseases

     • Biology and control of vector-     • Vaccines for childhood
     borne infections in Europe (CP).     bacterial diarrhoeal
     • Drug lead discovery against RNA    diseases (SICA).
     viruses (CP).                        • Comprehensive control
     • West Nile Virus infections,        of Neglected Infectious
     Chikungunya and/or Crimean           Diseases (SICA)
     Congo Haemorrhagic Fever (CP).       • Next generation of
     •Novel therapeutics against          researchers for
     influenza (FP7-Influenza-2010)       Neglected Infectious
     (CPs)                                Diseases (CA).
32
                                   The Health Theme
                      Structure and content of 2010 WP
                                  Pillar 2 :
             2. TRANSLATING RESEARCH FOR HUMAN HEALTH 
              2.4 Translational research in other major diseases
     2.4.1 Cancer
     • ERA-NET on translational cancer research in Europe (FP7-ERANET-
     2010-RTD).
     • Structuring translational cancer research between cancer research
     centres in Europe (NoE).
     • Structuring clinical research in paediatric and adolescent oncology in
     Europe (NoE).
     • Infectious agents and cancer in Africa (FP7-COORDINATED CALL FOR
     AFRICA-2010).
     • Structuring clinical research on rare cancers in adults (CPs) 2St.
     • Translational research on cancers with poor prognosis (CPs) 2St.
     • Predicting long-term side effects to cancer therapy (CPs) 2St.
     • Predicting individ. response & resistance to cancer therapy (CPs) 2St.
     • Optimising the delivery of (chemo)radiotherapy and/or surgery to
     cancer patients (CPs) 2St.
33
                                     The Health Theme
                        Structure and content of 2010 WP
                                     Pillar 2 :
              2. TRANSLATING RESEARCH FOR HUMAN HEALTH 
               2.4 Translational research in other major diseases
     2.4.2 Cardiovascular diseases          2.4.4 Rare diseases
     • Reducing in-stent thrombosis         • Clinical development of
     (CP).                                  substances with a clear potential
     • New approaches to reduce             as orphan drugs (CPs).
     ischemic damage to the heart           • ERA-Net on rare diseases (FP7-
     (CP).                                  ERANET-2010-RTD).
     • Identifying new therapeutic          2.4.5 Other chronic diseases
     targets in atrial fibrillation (CP).   • Initiation of allergic response,
     • Diastolic heart failure (CP).        genetic predisposition,
                                            biomarkers and identification of
                                            targets for therapy (CP).
       2.4.3 Diabetes and obesity           • Infection and dysbiosis as the
                                            triggers of the development of
                   Closed                   inflammatory processes…(CP)
34
                                   The Health Theme
                      Structure and content of 2010 WP
                                 Pillar 3:
       3. Optimising the delivery of healthcare to European citizens


     3.1 Translating the results of        3.2 Quality, efficiency and
     clinical research outcome into        solidarity of healthcare
     clinical practice…                    systems…

     • Better understanding of             • Financing systems' effect on
     dissemination and                     quality of healthcare (CPs).
     implementation strategies             • Risk adjustment algorithms for
     (CPs) 2St.                            better health insurance coverage
                                           (CPs).


           3.3 Enhanced health promotion and disease prevention

                                      Closed

35
                                    The Health Theme
                       Structure and content of 2010 WP
                                      Pillar 3:
         3. Optimising the delivery of healthcare to European citizens


     3.4 International Public Health & Health Systems
     • …key interventions and policies to address the human resource crisis
     in the health sector (FP7-COORDINATED CALL FOR AFRICA-2010).
     • …innovative intervention packages for maternal and new-born health
     in Africa (FP7-COORDINATED CALL FOR AFRICA-2010).
     • Building sustainable capacity for research for health in Africa (FP7-
     COORDINATED CALL FOR AFRICA-2010).
     • Assessment of migrants' health, disease patterns and impact on
     health systems (FP7-COORDINATED CALL FOR AFRICA-2010).
     • Assessment of migrants' health, disease patterns and impact on
     health systems (CA)
     • Impact and cost-effectiveness of existing major health programmes
     (SICA).
     • Financing models for accessible health care (SICA).
     See also Pillar 4, topic 4.2-5
36
                                       The Health Theme
                          Structure and content of 2010 WP
        Pillar 4 : OTHER ACTIONS ACROSS THE HEALTH THEME

     4.1 Coordination      4.2 Responding to EU policy needs
     and Support           • Off-Patent Medicines for Children (CPs).
     Actions across the    • International Paediatric initiative (NoE).
     Theme                 • Adverse Drug Reaction Research (CPs).
                           • International Pluripotent Stem Cell Registry (CA).
     • Promoting           • …evaluate and monitor health policy
     participation of      implementation and performance of EU funded
     high-technology       interventions in developing countries (SICA).
     research-intensive    • Impact of EU legislation on health research (SA).
     SMEs, operating in    • International forum for European life sciences
     the Health sector     funders and performers (CA).
     (CA).                 • Implementation by participating States of a Joint
                           Programming Initiative for combating
                           neurodegenerative diseases, in particular
                           Alzheimer's disease (CA).
37                                                                           ./..
                                 The Health Theme
                    Structure and content of 2010 WP
         Pillar 4 : OTHER ACTIONS ACROSS THE HEALTH THEME
                       4.2 Responding to EU policy needs
     4.2-9: Towards the replacement of repeated dose systemic toxicity
     testing in human safety assessment (FP7-HEALTH-2010-Joint-
     Research-Initiative-Commission-COLIPA).
     • Optimisation of current methodologies and development of novel
     methods to achieve functional differentiation of human-based
     target cells in vitro (CP).
     • Exploitation of organ-simulating cellular devices as alternatives
     for long-term toxicity testing (CP).
     • Establishment of endpoints and intermediate markers in human-
     based target cells with relevance for repeated dose systemic
     toxicity testing (CP).
     • Computational modelling and estimation techniques (CP).
     • Systems biology for the development of predictive causal
     computer models (CP).
     • Integrated data analysis and servicing (CP).
     • Coordination project (CP)
38
     Additional opportunity for SMEs,
     academy, patients organisations…
                  IMI




39
           The Innovative Medicines
                    Initiative (IMI)
        PPI to remove major bottlenecks in drug development,
                             acting where research is the key




         2 Billion EURO

     1 Billion Euro    1 Billion Euro




       Public                 Private
                Partnership

40
          IMI first call: 15 projects to be funded for €246 million investment
              (for more details see http://www.imi.europa.eu/calls-01_en.html)

                         Second call publication expected Mid-2009




     Pharmaceutical Industry          other Industry             Academics,
     (EFPIA companies)                 participants             SMEs, Patients

                                      IMI Research Project




          Research performed by                          Research performed by
     pharmaceutical industry funded                 public sector and SMEs funded by
 by own resources (= in kind contribution)            European Community (= cash
                                                              contribution)
41
                                           The Four Pillars of
                                        IMI Research Agenda

                                  SAFETY
                                  •Pre-clinical
                                  •Clinical


KNOWLEDGE MANAGEMENT                              EDUCATION & TRAINING
•Support to Safety and Efficacy                   •Training network
•Federated platform for data                      •Special courses
processing


                                   EFFICACY
                                   •General
                                   •Disease-specific




42
                             Contacts & Information
                                          for Health

     FP7 Health web site: http://cordis.europa.eu/fp7/health

     NCPs: http://cordis.europa.eu/fp7/health/support_en.html
     SMEsgoHealth: www.smesgohealth.org

     SMBioPower: www.smbiopower.eu/

     FP6 projects database: www.lifecompetence.eu

     Registration as an Expert: https://cordis.europa.eu/emmfp7/

     IMI: http://imi.europa.eu & www.imi-europe.org

     SMEs & Innovation: ludovica.serafini@ec.europa.eu
43
                                   The Health Directorate
        Director – Dr. Ruxandra Draghia-Akli:
        Medical and Public Health Research unit (F2)
        Head of unit: Dr. Manuel Hallen (manuel.hallen@ec.europa.eu)
        Deputy Head of Unit: Dr. Maria Vidal (maria-jose.vidal-ragout@ec.europa.eu)
        Head of sector Public Health: K. McCarthy (kevin.mccarthy@ec.europa.eu)
        Infectious Diseases unit (F3)
        Head of unit: Dr. Alain Vanvossel (alain.vanvossel@ec.europa.eu)
        Deputy Head of unit: Dr. Anna Lönnroth (anna.lonnroth@ec.europa.eu)
        Head of sector IMI : Dr. Irene Norstedt (irene.norstedt@ec.europa.eu)
        Genomics and Systems Biology unit (F4)
        Head of unit: Patrik Kolar (patrik.kolar@ec.europa.eu)
        Deputy Head of unit: Dr. B. Mulligan (bernard.mulligan@ec.europa.eu)
        Health Biotechnology unit (F5)
        Head of unit: Dr. Arnd Hoeveler (arnd.hoeveler@ec.europa.eu)
     Coordination unit (F1)             Admin. & Finance unit (F6)
     Head of unit: Stéphane Hogan       Head of unit: Georgios Zisimatos
     (stephane.hogan@ec.europa.eu)      (georgios.zisimatos@ec.europa.eu)
44
                                             SME definition

      Less than 250 employees,
      L Annual turnover less or equal to 50 million €
      M Balance sheet less or equal to 43 million €
      M The company must be independent

        For more details, see:
        http://ec.europa.eu/enterprise/enterprise_policy/sme_definitio
        n/index_en.htm

     Calculator for the auto-evaluation of SMEs : http://flt.uwe.be/

      Developed with the European Commission (PME TechWeb),
       NCP-Wallonie (L’Union Wallonne des Entreprises, Belgium) and
       EASI-WAL (l’Agence pour la simplification administrative en
       Wallonie, Belgium).

45

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:2
posted:2/25/2010
language:English
pages:45